Evidence map›Paper›PMID 39979691›Full record

ArticleBreast cancer (Tokyo, Japan)2025

SET-binding protein 1 (SETBP1) suppresses cell proliferation in estrogen receptor-positive breast cancer.

Yuki Ando, Takaaki Masuda, Naoki Hayashi, Keisuke Kosai, Shohei Shibuta, Yuya Ono, Tobo Taro, Hajime Otsu, Yuichi Hisamatsu, Tomoharu Yoshizumi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuki AndoDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Takaaki MasudaDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Naoki HayashiDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Keisuke KosaiDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Shohei ShibutaDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Yuya OnoDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Tobo TaroDepartment of Clinical Laboratory Medicine, Kyushu University, Beppu Hospital, Oita, Japan.
Hajime OtsuDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Yuichi HisamatsuDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Koshi MimoriDepartment of Surgery, Kyushu University, Beppu Hospital, 4546, Tsurumihara, Beppu Oita, 874-0838, Japan. kmimori@beppu.kyushu-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe single-nucleotide polymorphism rs6507583 at the promoter of SET-binding protein 1 (SETBP1) was implicated in estrogen receptor (ER)-positive breast carcinogenesis. Here, we evaluated the clinical and biological relevance of SETBP1 expression in ER-positive breast cancer (BC).

methodsThe associations between SETBP1 expression and clinical outcomes in BC patients were analyzed in independent cohorts. The localizations of SETBP1 expression in BC tissues were observed by immunohistochemical staining. Pathway analyses were conducted using TCGA dataset. In vitro proliferation assay, protein phosphatase 2A (PP2A) activity assay, and gene expression analysis were performed in SETBP1-knockdown ER-positive BC cells. We investigated the factors influencing SETBP1 mRNA expression using TCGA dataset. rs6507583 presence and SETBP1 mRNA expression in 11 mammary cell lines and 56 BC tissue samples were examined by target sequencing and RT-qPCR, respectively.

resultsSETBP1 was downregulated in BC cells compared with normal ductal epithelial cells. Low SETBP1 mRNA expression was an independent prognostic factor for poor recurrence-free survival. Pathway analyses revealed an inverse relationship between decreased SETBP1 expression and the expression of E2F, MYC, and G2M checkpoint target genes in BC tissues. SETBP1 knockdown promoted proliferation, inhibition of PP2A activity, and phosphorylation of MAPK in ER-positive BC. Low SETBP1 expression was influenced by high SETBP1 promoter methylation and DNA copy number SETBP1 deletion. SETBP1 expression with rs6507583 was lower than without rs6507583 in BC.

conclusionsWe demonstrated that low SETBP1 expression could be a poor prognostic biomarker that promotes ER-positive BC proliferation, possibly via phosphorylation of MAPK.

Indexed as

Breast NeoplasmsCarrier ProteinsNuclear ProteinsReceptors, EstrogenBiomarkers, TumorCell Line, TumorCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPolymorphism, Single NucleotidePrognosisPromoter Regions, GeneticBiomarkers, TumorCarrier ProteinsNuclear ProteinsReceptors, EstrogenBreast cancerER-positiveProliferationSETBP1SNP

Identifiers

PMID39979691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.